金陵藥業(000919.SZ)：上半年淨利預降87%-93%
格隆匯 7 月 13日丨金陵藥業(000919.SZ)公佈，預計上半年實現歸屬於上市公司股東的淨利潤1,590萬元-2,953萬元，比上年同期下降87%-93%。
公司本期歸屬於上市公司股東的淨利潤較上年同期下降的主要原因有：
1、報告期內公司預計非經常性損益對歸屬於上市公司股東的淨利潤的影響額約-3200萬元，主要是江蘇紫金農村商業銀行股份有限公司(以下簡稱“紫金銀行”)股票公允價值變動收益變動所致。按照財政部2017年修訂後的《企業會計準則第22號—金融工具確認和計量》和《企業會計準則第37號—金融工具列報》的相關規定，自2019年1月1日，公司對相關金融工具列報進行調整。其中，公司持有的紫金銀行的股票投資確認為交易性金融資產，由“可供出售金融資產”轉入“其他非流動金融資產”項目列報，後續該股票投資的公允價值變動將計入“公允價值變動收益”項目列報。
紫金銀行已於2019年1月3日在上海證券交易所主板發行上市，證券簡銀行已於2019年1月3日在上海證券交易所主板發行上市，證券簡稱“紫金銀行”，股票代碼：601860，發行價3.14元/股。公司持有紫金銀行35,296,430股，持股比例為0.96%。2019年上半年，公司確認紫金銀行股票的公允價值變動收益15,530.43萬元，由此增加歸屬於上市公司股東的淨利潤13,200.87萬元。而2020年上半年，公司確認紫金銀行股票公允價值變動收益-4,906.20萬元，由此減少歸屬於上市公司股東的淨利潤4,170.27萬元。
2、2020年初，新冠肺炎疫情爆發。在抗疫期間，公司所屬四家醫院積極響應政府號召，投入各種醫療資源及醫護人員全力抗擊新冠肺炎疫情，醫院正常醫療工作受到影響，與上年同期相比，門急診及住院病人數均出現較大幅度下降，導致公司2020年上半年醫療服務業收入和利潤都有較大幅度下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
